{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:47:42Z","timestamp":1791992862343,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.modpat.2026.101102","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:14:59Z","timestamp":1791990899000},"page":"101102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic and Transcriptomic Characterization of Angiosarcomas: Focus on Cardiac Origin"],"prefix":"10.1016","author":[{"given":"Tao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-4643","authenticated-orcid":false,"given":"Yingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2026.101102_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib2","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3","article-title":"Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1,240 patients from the French Federation of Cancer Centers Sarcoma Group","volume":"91","author":"Coindre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.modpat.2026.101102_bib3","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/annonc\/mdm381","article-title":"Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases","volume":"18","author":"Fayette","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00130404-200505000-00011","article-title":"A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy","volume":"11","author":"Fury","year":"2005","journal-title":"Cancer J"},{"key":"10.1016\/j.modpat.2026.101102_bib5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1245\/s10434-006-9335-y","article-title":"Treatment and outcome of 82 patients with angiosarcoma","volume":"14","author":"Abraham","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib6","first-page":"867","article-title":"Cutaneous angiosarcoma: a case series with prognostic correlation","volume":"50","author":"Morgan","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.modpat.2026.101102_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9960085","article-title":"Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology","volume":"2021","author":"Schott","year":"2021","journal-title":"Sarcoma"},{"key":"10.1016\/j.modpat.2026.101102_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102617","article-title":"Multimodality treatment of primary cardiac angiosarcoma: a systematic literature review","volume":"120","author":"Stergioula","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.modpat.2026.101102_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-pathmechdis-012418-012735","article-title":"Enabling precision oncology through precision diagnostics","volume":"15","author":"Brown","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.modpat.2026.101102_bib10","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1158\/2159-8290.CD-24-1476","article-title":"Precision oncology: 2024 in review","volume":"14","author":"Repetto","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2026.101102_bib11","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/2159-8290.CD-25-1784","article-title":"Precision oncology: 2025 in review","volume":"15","author":"Mai","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2026.101102_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1623327","article-title":"Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies","volume":"15","author":"Luong","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189159","article-title":"Molecular and immune pathobiology of human angiosarcoma","volume":"1879","author":"Lim","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.modpat.2026.101102_bib14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/ijc.34241","article-title":"One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing","volume":"151","author":"Li","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.modpat.2026.101102_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.03.005","article-title":"Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma","volume":"179","author":"Liu","year":"2023","journal-title":"Lung Cancer"},{"issue":"6322","key":"10.1016\/j.modpat.2026.101102_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.modpat.2026.101102_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.modpat.2026.101102_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrc3891","article-title":"Therapeutic opportunities within the DNA damage response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.modpat.2026.101102_bib19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.modpat.2026.101102_bib20","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2026.101102_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2026.101102_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012875","article-title":"POT1 and damage response malfunction trigger acquisition of somatic activating mutations in the VEGF pathway in cardiac angiosarcomas","volume":"8","author":"Calvete","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.modpat.2026.101102_bib23","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/0008-5472.CAN-14-1162","article-title":"A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells","volume":"74","author":"Kunze","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2026.101102_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1226289","article-title":"Targeting MCL-1 protein to treat cancer: opportunities and challenges","volume":"13","author":"Tantawy","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41388-024-03251-6","article-title":"Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma","volume":"44","author":"Takagi","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.modpat.2026.101102_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.humpath.2016.10.014","article-title":"Cardiac angiosarcoma: histopathologic, immunohistochemical, and cytogenetic analysis of 10 cases","volume":"60","author":"Leduc","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2026.101102_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1878-0261.13744","article-title":"Genomic landscape and preclinical models of angiosarcoma","volume":"19","author":"Benton","year":"2025","journal-title":"Mol Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphys.2018.00557","article-title":"The role of apelin in cardiovascular diseases, obesity and cancer","volume":"9","author":"Wysocka","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.modpat.2026.101102_bib29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jss.2015.12.042","article-title":"NPTX2 is associated with neoadjuvant therapy response in rectal cancer","volume":"202","author":"Karagkounis","year":"2016","journal-title":"J Surg Res"},{"key":"10.1016\/j.modpat.2026.101102_bib30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF\/GETO)","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.modpat.2026.101102_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2021.06.027","article-title":"An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma","volume":"154","author":"Agulnik","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2026.101102_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.101102_bib34","doi-asserted-by":"crossref","first-page":"24750","DOI":"10.18632\/oncotarget.25345","article-title":"Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma","volume":"9","author":"Chadwick","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2026.101102_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.modpat.2026.101102_bib36","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/cncr.34370","article-title":"Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study","volume":"128","author":"Ravi","year":"2022","journal-title":"Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:15:04Z","timestamp":1791990904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0893395226001456"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101102","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic and Transcriptomic Characterization of Angiosarcomas: Focus on Cardiac Origin","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101102"}}